DOCSLIB.ORG

Semi Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Semi-Annual Report March 31, 2021 (Unaudited) BlueStar Israel Technology ETF Ticker: ITEQ The Fund is a series of ETF Managers Trust. BlueStar Israel Technology ETF TABLE OF CONTENTS March 31, 2021 (Unaudited) Page Shareholder Letter 2 Growth of $10,000 Investment 3 Top 10 Holdings 4 Important Disclosures and Key Risk Factors 5 Portfolio Allocations 6 Schedule of Investments 7 Statement of Assets and Liabilities 11 Statement of Operations 12 Statements of Changes in Net Assets 13 Financial Highlights 14 Notes to the Financial Statements 15 Approval of Advisory Agreement and Board Considerations 24 Expense Example 27 Statement Regarding Liquidity Risk Management Program 28 Supplementary Information 29 Information About Portfolio Holdings 29 Information About Proxy Voting 29 Trustees and Officers Table 30 BlueStar Israel Technology ETF Dear Shareholder, On behalf of the entire team, we want to express our appreciation for the confidence you have placed in the BlueStar Israel Technology Exchange-Traded Fund (“ITEQ” or the “Fund”). The following information pertains to the fiscal period from October 1, 2020 to March 31, 2021. The Fund seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the BlueStar Israel Global Technology IndexTM (the “Index”). Over the 6-month period ending March 31, 2021, the total return for the Fund was 17.52% while the total return for the Index, which does not incur Fund expenses, was 17.75%. The best performers in the Fund on the basis of contribution to its return were SolarEdge Technologies, Novocure Ltd., Verint Systems Inc., Amdocs Ltd. and Kornit Digital Ltd. while the worst performers were Jfrog Ltd., Brainstorm Cell Therapeutics, Compugen Ltd., Check Point Software Technologies Ltd. and Lemonade Inc. At the end of the reporting period, the Fund saw an approximate allocation of 31.1% to Software, 16.3% to IT Services, 13.0% to Semiconductors & Semiconductor Equipment, 8.1% to Health Care Equipment & Supplies and 2.1% to Independent Power and Renewable Electricity Producers. The Fund was exposed predominately to Israel 62.0%, followed by the United States 23.5%. We continue to believe Israeli companies play an essential role in the global high technology value chain. Most technology users, from online shoppers to Fortune 500 companies, use Israeli technology applications and solutions every day without ever being aware of it. From cybersecurity and defense to clean energy and agriculture, Israeli innovations power some of the biggest names in the tech industry today. Even in industries where Israeli companies do not have dominant individual market share, the collective footprint of Israeli companies is significant in many key technology subsectors, and Israel- based Research & Development and non-public companies are usually significant contributors to that same sub-industry’s ecosystem. There is much ahead for Israeli Technology companies and we are thankful you have joined us. You can find further details about ITEQ by visiting www.etfmg.com, or by calling 1-844-ETF-MGRS. (1- 844-383-6477). Sincerely, Samuel Masucci III Chairman of the Board 2 BlueStar Israel Technology ETF Growth of $10,000 (Unaudited) $33,000 $28,000 $23,000 $18,000 $13,000 $8,000 11/02/201512/30/201503/31/201606/30/201609/30/201612/31/201603/31/201706/30/201709/30/201712/31/201703/31/201806/30/201809/30/201812/31/201803/31/201906/30/201909/30/201912/31/201903/31/202006/30/202009/30/202012/31/202003/31/2021 BlueStar Israel Technology ETF (NAV) BlueStar Israel Technology ETF (Market) S&P 500 Index BlueStar Israel Global Technology Index™ Since Value of Average Annual Returns 1 Year 5 Year Inception $10,000 Period Ended March 31, 2021 Return Return (11/2/2015) (3/31/2021) BlueStar Israel Technology ETF (NAV) 80.73% 22.58% 19.69% $ 26,449 BlueStar Israel Technology ETF (Market) 82.88% 22.47% 19.73% $ 26,489 S&P 500 Index 56.35% 16.29% 14.73% $ 21,031 BlueStar Israel Global Technology IndexTM 83.08% 23.76% 20.82% $ 27,830 Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance of the Fund may be lower or higher than the performance quoted. All performance is historical and includes reinvestment of dividends and capital gains. Performance data current to the most recent month end may be obtained by calling 1-844-ETF-MGRS (1-844-383-6477). The chart illustrates the performance of a hypothetical $10,000 investment made on November 2, 2015, and is not intended to imply any future performance. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions from the sales of Fund shares. The chart assumes reinvestment of capital gains and dividends, if any. The Index Returns do not reflect fees or expenses and are not available for direct investment. 3 BlueStar Israel Technology ETF Top Ten Holdings as of March 31, 2021 (Unaudited)* % of Total Security Investments 1 Wix.com, Ltd. 7.85% 2 SolarEdge Technologies, Inc. 7.52% 3 Check Point Software Technologies, Ltd. 6.66% 4 Nice, Ltd. 6.42% 5 Amdocs, Ltd. 6.38% 6 Novocure, Ltd. 5.48% 7 CyberArk Software, Ltd. 4.02% 8 Ormat Technologies, Inc. 3.71% 9 Fiverr International, Ltd. 3.26% 10 Elbit Systems, Ltd. 3.20% Top Ten Holdings = 54.50% of Total Investments * Current Fund holdings may not be indicative of future Fund holdings. 4 BlueStar Israel Technology ETF Important Disclosures and Key Risk Factors Past performance is not indicative of future return. A fund’s performance for very short time periods may not be indicative of future performance. ITEQ The BlueStar Israel Technology ETF (the “Fund”) seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the BlueStar Israel Global Technology Index (the “Index”). Investing involves risk, including the possible loss of principal. Shares of any ETF are bought and sold at market price (not NAV), may trade at a discount or premium to NAV and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Narrowly focused investments typically exhibit higher volatility. Investment in securities of Israeli companies involves risks that may negatively affect the value of your investment in the Fund. Among other things, Israel’s economy depends on imports of certain key items, such as crude oil, coal, grains, raw materials and military equipment. Foreign investing involves special risks such as currency fluctuations and political uncertainty. Funds that invest in smaller companies may experience greater volatility. Funds that emphasize investments in technology generally will experience greater price volatility. The Fund’s return may not match or achieve a high degree of correlation with the return of the Index. To the extent the Fund utilizes a sampling approach, it may experience tracking error to a greater extent than if the Fund had sought to replicate the Index. Diversification does not guarantee a profit, nor does it protect against a loss in a declining market. Unlike with an actively managed fund, the Fund’s adviser does not use techniques or defensive strategies designed to lessen the effects of market volatility or to reduce the impact of periods of market decline. This means that, based on market and economic conditions, the Fund’s performance could be lower than other types of funds that may actively shift their portfolio assets to take advantage of market opportunities or to lessen the impact of a market decline. Natural or environmental disasters, such as earthquakes, fires, floods, hurricanes, tsunamis and other severe weather-related phenomena generally, and widespread disease, including pandemics and epidemics, have been and may be highly disruptive to economies and markets, adversely impacting individual companies, sectors, industries, markets, currencies, interest and inflation rates, credit ratings, investor sentiment, and other factors affecting the value of the Fund’s investments. Given the increasing interdependence among global economies and markets, conditions in one country, market, or region are increasingly likely to adversely affect markets, issuers, and/or foreign exchange rates in other countries, including the U.S. Any such events could have a significant adverse impact on the value of the Fund’s investments. ETF Managers Group LLC is the investment advisor to the Fund. The Fund is distributed by ETFMG Financial LLC. ETF Managers Group LLC and ETFMG Financial LLC are wholly owned subsidiaries of Exchange Traded Managers Group LLC (collectively, “ETFMG”). ETFMG is not affiliated with MV Index Solutions GmbH or its affiliates. 5 BlueStar Israel Technology ETF PORTFOLIO ALLOCATIONS As of March 31, 2021 (Unaudited) BlueStar Israel Technology ETF As a percent of Net Assets: Gibraltar 1.2% Guernsey 6.4 Israel 62.0 Jersey 5.5 United Kingdom 0.9 United States 23.5 Short-Term and other Net Assets (Liabilities) 0.5 100.0% 6 BlueStar Israel Technology ETF Schedule of Investments March 31, 2021 (Unaudited) Shares Value COMMON STOCKS - 99.5% Gibraltar - 1.2% Hotels, Restaurants & Leisure - 1.2% 888 Holdings PLC 430,342 $ 2,343,426 Guernsey - 6.4% IT Services - 6.4% Amdocs, Ltd. 182,972 12,835,486 Israel - 62.0% Aerospace & Defense - 3.7% Elbit Systems, Ltd. 45,467 6,428,839 RADA Electronic Industries, Ltd. (a) 83,939 1,008,107 Total Aerospace & Defense 7,436,946 Biotechnology - 0.7% Kamada, Ltd. (a) 109,088 665,994 UroGen Pharma, Ltd. (a)(b) 39,692 773,200 Total Biotechnology 1,439,194 Capital Markets - 0.4% Electreon Wireless, Ltd.
Recommended publications
  • List of Marginable OTC Stocks

    List of Marginable OTC Stocks

    List of Marginable OTC Stocks @ENTERTAINMENT, INC. ABACAN RESOURCE CORPORATION ACE CASH EXPRESS, INC. $.01 par common No par common $.01 par common 1ST BANCORP (Indiana) ABACUS DIRECT CORPORATION ACE*COMM CORPORATION $1.00 par common $.001 par common $.01 par common 1ST BERGEN BANCORP ABAXIS, INC. ACETO CORPORATION No par common No par common $.01 par common 1ST SOURCE CORPORATION ABC BANCORP (Georgia) ACMAT CORPORATION $1.00 par common $1.00 par common Class A, no par common Fixed rate cumulative trust preferred securities of 1st Source Capital ABC DISPENSING TECHNOLOGIES, INC. ACORN PRODUCTS, INC. Floating rate cumulative trust preferred $.01 par common $.001 par common securities of 1st Source ABC RAIL PRODUCTS CORPORATION ACRES GAMING INCORPORATED 3-D GEOPHYSICAL, INC. $.01 par common $.01 par common $.01 par common ABER RESOURCES LTD. ACRODYNE COMMUNICATIONS, INC. 3-D SYSTEMS CORPORATION No par common $.01 par common $.001 par common ABIGAIL ADAMS NATIONAL BANCORP, INC. †ACSYS, INC. 3COM CORPORATION $.01 par common No par common No par common ABINGTON BANCORP, INC. (Massachusetts) ACT MANUFACTURING, INC. 3D LABS INC. LIMITED $.10 par common $.01 par common $.01 par common ABIOMED, INC. ACT NETWORKS, INC. 3DFX INTERACTIVE, INC. $.01 par common $.01 par common No par common ABLE TELCOM HOLDING CORPORATION ACT TELECONFERENCING, INC. 3DO COMPANY, THE $.001 par common No par common $.01 par common ABR INFORMATION SERVICES INC. ACTEL CORPORATION 3DX TECHNOLOGIES, INC. $.01 par common $.001 par common $.01 par common ABRAMS INDUSTRIES, INC. ACTION PERFORMANCE COMPANIES, INC. 4 KIDS ENTERTAINMENT, INC. $1.00 par common $.01 par common $.01 par common 4FRONT TECHNOLOGIES, INC.
  • Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67th Pctl $ 745,214,477.91 $ 23.96 225,966.94 801 33rd Pctl $ 199,581,478.89 $ 10.09 53,054.83 2399 Ticker_ Listing_ Effective_ Revised Symbol Security_Name Exchange Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M AAMC Altisource Asset Management Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L AEL American Equity Inv Life Hldg Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L AHL ASPEN Insurance Holding Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Advancing Cell Therapeutic Products for Clinical Use

    Advancing Cell Therapeutic Products for Clinical Use

    Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc.
  • March 31, 2021

    March 31, 2021

    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • Market Cap Close ADV

    Market Cap Close ADV

    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______

    Biolinerx Ltd. (Translation of Registrant’S Name Into English) ______

    SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2018 _______________________ BioLineRx Ltd. (Translation of registrant’s name into English) _______________________ 2 HaMa’ayan Street Modi’in 7177871, Israel (Address of Principal Executive Offices) _______________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☑ Form 40-F ☐ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: Yes ☐ No ☑ The registrant hereby announces that it has entered into an employment agreement with Hillit Mannor Shachar, M.D., MBA, M.S.F.S., to serve as its new Vice President Business Development, effective April 1, 2018. Dr. Shachar will be responsible for BioLineRx’s business development, commercialization of assets and pipeline strategy. Dr. Shachar joins BioLineRx with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI), a leading developer of placenta-based cell therapy products, and Director of New Business Development at West Pharmacuetical Services. In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, Nektar Therapeutics, Orex Computed Radiography, Kodak and Transpharma Medical.
  • Audiocodes AGM Proxy Statement 2021

    Audiocodes AGM Proxy Statement 2021

    Exhibit 99.1 August 10, 2021 Dear Shareholder, You are cordially invited to attend the 2021 Annual General Meeting of Shareholders (the “Meeting”) of AudioCodes Ltd. (the “Company” or “AudioCodes”), to be held on September 14, 2021, at 2:00 p.m., local time, or at any adjournment or postponement thereof, for the purposes set forth herein and in the enclosed Notice of Annual General Meeting of Shareholders. The Meeting will be held at the offices of the Company located at 1 Hayarden Street, Airport City, Lod 7019900, Israel. The telephone number at that address is +972-3-976-4000. The health and well-being of our employees and shareholders are paramount, and we are closely monitoring developments related to the novel coronavirus, or COVID-19. Although we intend to hold the Meeting in person, we are sensitive to the public health and travel concerns our shareholders may have and the protocols that governments may impose. We reserve the right to convert to a virtual only meeting format should meeting in person become unsafe as a result of COVID-19. If we convert to a virtual only online meeting, we will announce the decision to do so in advance and provide instructions for shareholder participation in the virtual meeting in a Form 6-K filed with the Securities and Exchange Commission. As always, we encourage you to vote your shares prior to the Meeting. At the Meeting, shareholders will be asked to consider and vote on the matters listed in the enclosed Notice of Annual General Meeting of Shareholders. AudioCodes’ Board of Directors recommends that you vote FOR all of the proposals listed in the Notice.
  • PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)

    PLURISTEM THERAPEUTICS INC. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-31392 PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Nevada 98-0351734 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905 (Address of principal executive offices) (Zip Code) Registrant's telephone number 011-972-74-7107259 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock, par value $0.00001 Nasdaq Capital Market Securities registered pursuant to Section 12(g) of the Act: None. (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • Life Sciences in Israel

    Life Sciences in Israel

    STATE OF ISRAEL Ministry of Industry Trade and Labor Investment Promotion Center Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Table of Contents .......................................... 3 Israel: A Powerhouse of Opportunities ............................................................ 3 Israel’s Life Science Sectors Medical Devices ........................................................................ 4 Healthcare IT ............................................................................ 4 BioPharmaceutical .................................................................... 7 Israel’s Biomedical Engineering - ................................................... 11 Spotlight on Stem Cell Research ....................................... 15 Israel’s Life Sciences Competitive Edge ..................................................................... 19 Government Support 2 Life Sciences in Israel Israel: A Powerhouse of Opportunities Why Israel’s Life Sciences Over the last decade, Israel has introduced a wealth of groundbreaking More than 1,000 Life and valuable innovations in Life Sciences. Israel’s Life Sciences sector Sciences Companies - is supported by a strong foundation of academic excellence, including Biopharma and Medical some of the world’s leading research institutes, renowned R&D Devices facilities and cutting-edge medical centers. Bolstered by a highly skilled Over 1/3 of LS Start-Ups workforce, a flourishing high-tech environment, and an entrepreneurial already generate revenue
  • Alphabetical Listing by Company Name

    Alphabetical Listing by Company Name

    FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2015 Alphabetical Listing by Company Name COMPANY COUNTRY MARKET 21 Vianet Group Inc. Cayman Islands Global Market 37 Capital Inc. Canada OTC 500.com Ltd. Cayman Islands NYSE 51Job, Inc. Cayman Islands Global Market 58.com Inc. Cayman Islands NYSE ABB Ltd. Switzerland NYSE Abbey National Treasury Services plc United Kingdom NYSE - Debt Abengoa S.A. Spain Global Market Abengoa Yield Ltd. United Kingdom Global Market Acasti Pharma Inc. Canada Capital Market Acorn International, Inc. Cayman Islands NYSE Actions Semiconductor Co. Ltd. Cayman Islands Global Market Adaptimmune Ltd. United Kingdom Global Market Adecoagro S.A. Luxembourg NYSE Adira Energy Ltd. Canada OTC Advanced Accelerator Applications SA France Global Market Advanced Semiconductor Engineering, Inc. Taiwan NYSE Advantage Oil & Gas Ltd. Canada NYSE Advantest Corp. Japan NYSE Aegean Marine Petroleum Network Inc. Marshall Islands NYSE AEGON N.V. Netherlands NYSE AerCap Holdings N.V. Netherlands NYSE Aeterna Zentaris Inc. Canada Capital Market Affimed N.V. Netherlands Global Market Agave Silver Corp. Canada OTC Agnico Eagle Mines Ltd. Canada NYSE Agria Corp. Cayman Islands NYSE Agrium Inc. Canada NYSE AirMedia Group Inc. Cayman Islands Global Market Aixtron SE Germany Global Market Alamos Gold Inc. Canada NYSE Alcatel-Lucent France NYSE Alcobra Ltd. Israel Global Market Alexandra Capital Corp. Canada OTC Alexco Resource Corp. Canada NYSE MKT Algae Dynamics Corp. Canada OTC Algonquin Power & Utilities Corp. Canada OTC Alianza Minerals Ltd. Canada OTC Alibaba Group Holding Ltd. Cayman Islands NYSE Allot Communications Ltd. Israel Global Market Almaden Minerals Ltd.
  • DSP Group Annual Report 2020

    DSP Group Annual Report 2020

    DSP Group Annual Report 2020 Form 10-K (NASDAQ:DSPG) Published: March 11th, 2020 PDF generated by stocklight.com SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TOSECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to________ Commission File Number 001-35256 DSP GROUP, INC. (Exact name of registrant as specified in its charter) Delaware 94-2683643 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation and organization) 2055 Gateway Place, Suite 480, San Jose, California 95110 (Address of principal executive offices, including zip code) 408-986-4300 (Registrant’s telephone number) Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.001 per share (Title of class) Securities registered pursuant to Section 12(b) of the Act Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.001 per share DSPG The NASDAQ Stock Market LLC Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.